South Korea Orphan Drugs Market Size and Forecast 2032

South Korea Orphan Drugs Market Report by Drug Type (Biological, Non-Biological), Disease Type (Oncology, Hematology, Neurology, Cardiovascular, and Others), Phase (Phase I, Phase II, Phase III, Phase IV), Top Selling Drugs (Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A21486

Buy Now New Year Sale

Market Overview:

South Korea orphan drugs market size reached US$ 4.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach US$ 10.3 Billion by 2033, exhibiting a growth rate (CAGR) of 10.80% during 2025-2033. The launch of favorable policies by government bodies to inhibit the spread of contagious diseases is primarily driving the regional market.

Report Attribute	Key Statistics
Base Year	2024
Forecast Years	2025-2033
Historical Years	2019-2024
Market Size in 2024	US$ 4.1 Billion
Market Forecast in 2033	US$ 10.3 Billion
Market Growth Rate (2025-2033)	10.80%

Orphan drugs are pharmaceutical products designed for the diagnosis, prevention, and treatment of rare medical disorders. These drugs are specifically developed to address a particular public health need and typically have a limited market due to their production for a small patient population. They prove effective against a range of conditions, including oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. Conditions such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma fall under the category of orphan drug applications. These medical conditions are often characterized by being life-threatening, chronic, progressive, degenerative, and disabling, necessitating tailored treatment options that are effective in addressing their unique symptoms.

South Korea Orphan Drugs Market Trends:

The South Korea orphan drugs market has emerged as a critical component within the nation's healthcare landscape, addressing the specific medical needs of individuals affected by rare disorders. The regional market offers effective solutions against a spectrum of medical conditions, encompassing oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. Additionally, conditions, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma fall under the ambit of orphan drug applications. Moreover, these medical disorders often present life-threatening, chronic, progressive, degenerative, and disabling characteristics, necessitating specialized treatment alternatives that can effectively address their distinctive symptoms. Besides this, as South Korea continues to advance in healthcare innovation, the orphan drugs market becomes integral in providing targeted and efficacious solutions for patients facing rare medical challenges. The focus on precision medicine and tailored treatments aligns with the nation's commitment to delivering advanced healthcare solutions. The South Korea stands as a pivotal player in the provision of specialized therapies that enhance the quality of life for individuals grappling with rare disorders, which is expected to fuel the regional market in the coming years.

South Korea Orphan Drugs Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on drug type, disease type, phase, top selling drugs, and distribution channel.

Drug Type Insights:

Biological
Non-Biological

The report has provided a detailed breakup and analysis of the market based on the drug type. This includes biological and non-biological.

Disease Type Insights:

Oncology
Hematology
Neurology
Cardiovascular
Others

A detailed breakup and analysis of the market based on the disease type have also been provided in the report. This includes oncology, hematology, neurology, cardiovascular, and others.

Phase Insights:

Phase I
Phase II
Phase III
Phase IV

The report has provided a detailed breakup and analysis of the market based on the phase. This includes phase I, phase II, phase III, and phase IV.

Top Selling Drugs Insights:

Revlimid
Rituxan
Copaxone
Opdivo
Keytruda
Imbruvica
Avonex
Sensipar
Soliris
Others

A detailed breakup and analysis of the market based on the top selling drugs have also been provided in the report. This includes revlimid, rituxan, copaxone, opdivo, keytruda, imbruvica, avonex, sensipar, soliris, and others.

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Stores
Others

The report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online stores, and others.

Regional Insights:

Seoul Capital Area
Yeongam (Southeastern Region)
Honam (Southwestern Region)
Hoseo (Central Region)
Others

The report has also provided a comprehensive analysis of all the major regional markets, which include Seoul Capital Area, Yeongam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), and Others.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

South Korea Orphan Drugs Market Report Coverage:

Report Features	Details
Base Year of the Analysis	2024
Historical Period	2019-2024
Forecast Period	2025-2033
Units	US$ Billion
Scope of the Report	Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment: Drug Type Disease Type Phase Top Selling Drugs Distribution Channel Region
Drug Types Covered	Biological, Non-Biological
Disease Types Covered	Oncology, Hematology, Neurology, Cardiovascular, Others
Phases Covered	Phase I, Phase II, Phase III, Phase IV
Top Selling Drugs Covered	Revlimid, Rituxan, Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, Others
Distribution Channels Covered	Hospital Pharmacies, Retail Pharmacies, Online Stores, Others
Regions Covered	Seoul Capital Area, Yeongnam (Southeastern Region), Honam (Southwestern Region), Hoseo (Central Region), Others
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 3699 Five User License: US$ 4699 Corporate License: US$ 5699
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report:

How has the South Korea orphan drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the South Korea orphan drugs market?
What is the breakup of the South Korea orphan drugs market on the basis of drug type?
What is the breakup of the South Korea orphan drugs market on the basis of disease type?
What is the breakup of the South Korea orphan drugs market on the basis of phase?
What is the breakup of the South Korea orphan drugs market on the basis of top selling drugs?
What is the breakup of the South Korea orphan drugs market on the basis of distribution channel?
What are the various stages in the value chain of the South Korea orphan drugs market?
What are the key driving factors and challenges in the South Korea orphan drugs?
What is the structure of the South Korea orphan drugs market and who are the key players?
What is the degree of competition in the South Korea orphan drugs market?

Key Benefits for Stakeholders:

IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the South Korea orphan drugs market from 2019-2033.
The research report provides the latest information on the market drivers, challenges, and opportunities in the South Korea orphan drugs market.
Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the South Korea orphan drugs industry and its attractiveness.
Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Purchase Options New Year Sale

Inquire Before Buying

Speak to an Analyst

Request Brochure

Request Customization

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.